Document Type : Original Article

Authors

1 Department of Pathology, School of Medicine, Zagazig University, Zagazig , Egypt

2 Department of Pathology, School of Medicine, Zagazig University, Zagazig, Egypt

3 Department of Clinical Oncology and Nuclear Medicine, School of Medicine, Zagazig University, Zagazig, Egypt

10.30476/mejc.2021.87068.1393

Abstract

Background: Programmed death- ligand 1(PD-L1) acts as an immune checkpoint inhibitor. Phosphatase and tensin homolog (PTEN) is a somatically mutated tumor suppressor gene in numerous types of human cancer. The current study aimed to assess the prognostic value of PD-L1 and PTEN expression in prostatic cancer patients, as well as their relationship with the clinicopathological features of the disease.
Method: A total of 55 needle biopsy specimens were retrospectively diagnosed as prostatic adenocarcinoma. Immunohistochemical staining with PD-L1 and PTEN were evaluated in all the cases. The patients were followed up for 5 years in order to detect disease recurrence and survival.
Results: PD-L1 expression in Prostate cancer was positively correlated with high PSA, higher Gleason score, advanced stage, higher tumor relapse, and worse disease-free and overall survival (P < 0.001). PTEN loss was significantly associated with high PSA, higher Gleason score ˃7, advanced tumor stage, tumor relapse, and worse disease-free and overall survival (P ˂ 0.001). We observed a significant negative correlation between PTEN and PD-L1.
Conclusion: PDL-1 and PTEN are prognostic markers for prostate cancer, which can differentiate between the patients who are at a high risk of disease progression and may successively provide novel targeted therapies.

Keywords

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.30476/mejc.2021.87068.1393